portfolio strategy

Six oncology breakthroughs from Mainland China: Takeaways from ASCO 2021

Clarivate oncology experts analyzed ASCO 2021 abstracts from Mainland China to highlight key trends and breakthrough treatments that are expected to impact the oncology landscape. Mainland Chinese companies were strongly represented at the 2021 ASCO Annual Meeting. As part of our Drugs to Watch™ series spotlighting therapies expected to have significant impact on drug landscapes, […]

10 takeaways from the Clarivate Innovation Forum

Of all the factors driving innovation, organisations across a spectrum of industries find three Cs in common— curiosity, commitment and creativity. At the 2021 Clarivate Virtual Innovation Forum for the Middle East, Africa and Russia region which took place in May, speakers, panellists and moderators emphasised these factors and the power they have to drive […]

Impact of COVID-19 vaccine rollout on medtech recovery

The COVID-19 pandemic impacted the fundamental operations of all healthcare stakeholders. The ability to predict the outcomes of the pandemic and the speed of recovery for medtech markets has been challenged by the lack of historical data. This article is an executive summary of a new report from Clarivate assessing how COVID-19 vaccine rollouts will […]

For the 2021 Journal Citation Reports, a new visual experience

This is the third in a series of updates to provide information on the 2021 Journal Citation Reports release. From its origins as a print edition in 1975, Journal Citation Reports™ (JCR) has come far. Indeed, for the first 14 years of its existence, JCR was bundled with the annual print volumes of the Science […]

Top 10 oncology breakthroughs shared at ASCO 2021

Clarivate oncology experts analyzed more than 2,400 ASCO abstracts and selected the top 10 based on their expected impact on the drug treatment landscape. In the following article, we share our analysis of these exciting breakthroughs, data and takeaways for life sciences executives.   “Equity: Every Patient. Everyday. Everywhere” The ASCO Annual Meeting is the […]

PICC vascular access market: competitive factors and strategies

Clarivate vascular expert Jackie Lui shares findings from her analysis of the PICC vascular access market, reviewing key competitive strategies and takeaways for strategists. While some argue that peripherally inserted central catheters (PICC) have become overused, their refined and more careful use — mainly as infusion devices — remains  beneficial. Advantages of PICCs as vascular […]

What drives the therapy selection test market?

Clarivate medtech expert Sophia Quraishi reviews key factors driving increased demand for premium-priced therapy selection tests.   Therapy selection tests are a form of liquid biopsy, which involve sequencing substrates isolated from bodily fluids, such as blood, saliva or urine. This approach is less invasive, can be used more often and is more cost effective […]

Key ESMO Highlights 2020

As a result of the current COVID-19 pandemic, the annual ESMO Congress was held virtually between 19th and 21st September 2020. Over 2,100 oral presentations and posters were presented, showcasing exciting novel data across oncology, with the ultimate aim of improving cancer patient care. Here DRG/Clarivate highlights the most impactful presentations on drug treatment landscapes. […]

GSK’s first-in-class anti-BCMA therapy wins regulatory approval

GSK’s BLENREP has become the first anti-BCMA therapy to secure a position in the treatment algorithm of multiple myeloma (relapsed or refractory setting). This approval was a highly anticipated event and significant for the multiple myeloma treatment landscape because it helps address an important unmet need for patients who have received at least four prior […]

Aducanumab: On the verge of making history in Alzheimer’s disease

When Biogen and Eisai terminated aducanumab’s Phase III program in early Alzheimer’s disease (AD) for futility in March 2019, a mere two months after Roche discontinued crenezumab, we wondered if it was the end of the line for anti-beta amyloid (Aβ) treatment in symptomatic AD. Shortly after the announcement, we removed all late-phase anti-Aβ drugs […]